All articles tagged with #macleods pharma
The FDA has issued a Class II recall for 3,744 bottles of a generic triple-combination blood pressure medication manufactured by Macleods Pharma USA. The affected lots failed dissolution testing, meaning the pills may not release active ingredients properly. Patients are advised to check lot numbers and consult their doctors before stopping treatment.
The FDA has classified a nationwide recall of over 3,700 bottles of a generic triple-combination blood pressure medication as Class II. Manufactured by Macleods Pharma USA, the affected lots failed dissolution testing, meaning the pills may not release active ingredients properly. Patients are advised to check lot numbers and consult their doctors before stopping treatment.
The FDA has issued a Class II recall for over 3,700 bottles of a generic triple-combination blood pressure medication manufactured by Macleods Pharma USA. The affected lots failed dissolution testing, meaning the pills may not release active ingredients properly. Patients are advised to check lot numbers and consult their doctors before stopping treatment.
The FDA has classified a nationwide recall of over 3,700 bottles of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets as Class II. Initiated by Macleods Pharma USA on October 7, the recall addresses failed dissolution specifications, meaning the pills may not release active ingredients properly. While the FDA advises patients not to stop taking the medication abruptly, they should consult their doctors. This follows a separate October recall of Viatris telmisartan tablets.
The FDA has classified a nationwide recall of over 3,700 bottles of a generic triple-combination blood pressure medication as Class II. Manufactured by Macleods Pharma USA, the affected lots failed dissolution testing, meaning the pills may not release active ingredients properly. While brand-name versions are unaffected, patients are advised to check lot numbers and consult doctors before stopping treatment.